AU8370891A - New recombinant herpes viruses, a vaccine based on these recombinants, their preparation process, genes, vectors and plasmids used in this process - Google Patents

New recombinant herpes viruses, a vaccine based on these recombinants, their preparation process, genes, vectors and plasmids used in this process

Info

Publication number
AU8370891A
AU8370891A AU83708/91A AU8370891A AU8370891A AU 8370891 A AU8370891 A AU 8370891A AU 83708/91 A AU83708/91 A AU 83708/91A AU 8370891 A AU8370891 A AU 8370891A AU 8370891 A AU8370891 A AU 8370891A
Authority
AU
Australia
Prior art keywords
recombinants
genes
vectors
herpes viruses
plasmids used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU83708/91A
Other versions
AU657488B2 (en
Inventor
Matthew Mckinley Binns
Arielle Rey-Senelonge
Michel Emile Albert Riviere
Louis Joseph Norman Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial SAS filed Critical Merial SAS
Publication of AU8370891A publication Critical patent/AU8370891A/en
Application granted granted Critical
Publication of AU657488B2 publication Critical patent/AU657488B2/en
Assigned to MERIAL reassignment MERIAL Request to Amend Deed and Register Assignors: RHONE MERIEUX
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU83708/91A 1990-09-07 1991-09-06 New recombinant herpes viruses, a vaccine based on these recombinants, their preparation process, genes, vectors and plasmids used in this process Ceased AU657488B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9011146 1990-09-07
FR909011146A FR2666589B1 (en) 1990-09-07 1990-09-07 NOVEL RECOMBINANT HERPIC VIRUSES, VACCINE BASED ON SUCH RECOMBINANTS, PREPARATION METHOD THEREOF, GENES, VECTORS AND PLASMIDS USED IN THIS PROCESS.

Publications (2)

Publication Number Publication Date
AU8370891A true AU8370891A (en) 1992-03-12
AU657488B2 AU657488B2 (en) 1995-03-16

Family

ID=9400177

Family Applications (1)

Application Number Title Priority Date Filing Date
AU83708/91A Ceased AU657488B2 (en) 1990-09-07 1991-09-06 New recombinant herpes viruses, a vaccine based on these recombinants, their preparation process, genes, vectors and plasmids used in this process

Country Status (5)

Country Link
EP (1) EP0477056A1 (en)
JP (1) JPH05168473A (en)
AU (1) AU657488B2 (en)
CA (1) CA2050850A1 (en)
FR (1) FR2666589B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU636247B2 (en) * 1990-08-24 1993-04-22 Michigan State University Genes of marek's disease virus glycoproteins gd, gi and ge
AU669849B2 (en) * 1991-06-28 1996-06-27 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Attenuated revertant serotype 1 Marek's disease vaccine

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5928648A (en) * 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5853733A (en) * 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
DE69332480T2 (en) * 1992-07-30 2003-07-17 Akzo Nobel N.V., Arnheim/Arnhem VACCINE VECTORS FROM RECOMBINANT CAT HERPESVIRUS
US6875856B2 (en) 1993-09-24 2005-04-05 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof
FR2719056B1 (en) * 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformed to express gD in vitro.
FR2728795B1 (en) * 1994-12-30 1997-03-21 Rhone Merieux AVIAN RECOMBINANT LIVING VACCINE USING AVIAN HERPES VIRUS AS A VECTOR
FR2728794B1 (en) * 1994-12-30 1997-03-21 Rhone Merieux AVIAN RECOMBINANT VACCINE BASED ON AVIAN HERPES VIRUS, PARTICULARLY AGAINST GUMBORO DISEASE
AU4489896A (en) * 1994-12-30 1996-07-24 Rhone Merieux Avian recombinant live vaccine
FR2757061B1 (en) * 1996-12-16 1999-03-26 Rhone Merieux AVIAN RECOMBINANT LIVING VACCINE USING AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS AS A VECTOR
EP2768529A1 (en) 2011-10-21 2014-08-27 Intervet International B.V. Recombinant nonpathogenic mdv vector providing multivalent immunity
CN103890183A (en) 2011-10-21 2014-06-25 英特维特国际股份有限公司 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2779447B2 (en) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 Method for producing recombinant gene using attenuated Marek's disease virus vector and recombinant of the virus
WO1990002802A2 (en) * 1988-09-13 1990-03-22 Institute For Animal Health Limited Viral nucleotide sequences
EP0431668B1 (en) * 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
DE69101683T2 (en) * 1990-07-30 1994-07-21 Akzo Nv Recombinant Mareks disease virus.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU636247B2 (en) * 1990-08-24 1993-04-22 Michigan State University Genes of marek's disease virus glycoproteins gd, gi and ge
AU669849B2 (en) * 1991-06-28 1996-06-27 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Attenuated revertant serotype 1 Marek's disease vaccine

Also Published As

Publication number Publication date
FR2666589A1 (en) 1992-03-13
FR2666589B1 (en) 1994-08-05
AU657488B2 (en) 1995-03-16
CA2050850A1 (en) 1992-03-08
EP0477056A1 (en) 1992-03-25
JPH05168473A (en) 1993-07-02

Similar Documents

Publication Publication Date Title
AU657488B2 (en) New recombinant herpes viruses, a vaccine based on these recombinants, their preparation process, genes, vectors and plasmids used in this process
USD361382S (en) Dental material curing apparatus
GB2246784B (en) Herpes virus recombinant poxvirus vaccine
AU4325089A (en) Viral vaccines
IL110284A0 (en) Viral vectors and their use in gene therapy
GB2210621B (en) Two micron yeast plasmid vector
FR2712603B1 (en) Recombinant viruses, preparation and use in gene therapy.
EP0299242A3 (en) Heterologous viral peptide particle immunogens
HUT60506A (en) Process for producing non-replicable, recombinant retrovirus particles and antiviral and immunogenic preparations
AU7442996A (en) Recombinant herpes virus vectors for expression in neuronal cells
AU2497292A (en) Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
AU3636189A (en) Hiv-2 virus variants
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
AU600130B2 (en) New, color pure iron oxide pigments, a process for their preparation and their use
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof
AU5350990A (en) Vaccinia vectors, vaccinia genes and expression products thereof
AU1738192A (en) LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
AU7138091A (en) Fluorourethane group-containing polymers made from ethylenically unsaturated monomers, process for their preparation and their use
AU6358190A (en) Polypeptide vaccines against foot-and-mouth disease virus
EP0586065A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
NZ213249A (en) Protein antigen, dna, plasmid, transformed microorganism and influenza vaccine
ZA907656B (en) A dna sequence,an anther-specific promoter and the use thereof
AU5836390A (en) Human lymphoma-associated virus
CA2148369A1 (en) Actinobacillus pleuropneumoniae outer membrane lipoprotein a and uses thereof
AU3232995A (en) Hepatitis a virus deletion mutants and vaccine formulations containing the same

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired